A novel nanobody therapy caplacizumab (Cablivi) has been approved by the TGA as a treatment for acquired Thrombotic Thrombocytopenic Purpura (aTTP). The humanised nanobody therapy is approved in Australia to treat adults experiencing an episode of aTTP in conjunction with plasma exchange and immunosuppression. According to manufacturer Sanofi, caplacizumab binds to the protein von Willebrand ...
Caplacizumab approved for acquired Thrombotic Thrombocytopenic Purpura
By Michael Woodhead
13 May 2020